15 July 2021, 07:30 CEST, Belgium: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir's innovative therapies at Mithra's integrated R&D and manufacturing platform, Mithra CDMO.

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 15 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2021 05:34:09 UTC.